Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1899410 | 0.87 | NPSR1 (0.57) | NPSR1KMT2AHDAC1HDAC6KIF11 | |
| SCHEMBL2452487 | 0.84 | CYP1A2 (0.58) | HDAC6HDAC2HDAC8ALDH1A1MAPT | |
| SCHEMBL933329 | 0.83 | MTNR1A (0.47) | ALDH1A1KDM4E | |
| SCHEMBL17123631 | 0.82 | NPSR1 (0.49) | NPSR1KMT2AHDAC1HDAC6KIF11 | |
| SCHEMBL16089565 | 0.82 | CYP1A2 (0.42) | ALDH1A1MAPTRAB9AHPGDFOLH1 | |
| SCHEMBL4341722 | 0.80 | CYP1A2 (0.58) | NPSR1KMT2AHDAC1HDAC6KIF11 | |
| SCHEMBL1903558 | 0.80 | NPSR1 (0.50) | NPSR1KMT2AHDAC1HDAC6KIF11 | |
| SCHEMBL13039575 | 0.80 | HDAC1 (0.51) | NPSR1KMT2AHDAC1HDAC6KIF11 | |
| SCHEMBL14174608 | 0.80 | NOS1 (0.51) | NPSR1KMT2AHDAC1HDAC6KIF11 | |
| SCHEMBL171282 | 0.80 | MMP13 (0.60) | NPSR1KMT2AHDAC1HDAC6KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3012250-B1 | ISOQUINOLINE MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2017-11-08 | — | — | EP | disclosed |
| US-20170216335-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | PERICOR THERAPEUTICS INC (US) | 2017-08-03 | — | — | US | disclosed |
| US-20170216335-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | PERICOR THERAPEUTICS INC (US) | 2017-08-03 | — | — | US | disclosed |
| US-9539274-B2 | Methods, compositions, and formulations for preventing or reducing adverse effects in a patient | PERICOR THERAPEUTICS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9539274-B2 | Methods, compositions, and formulations for preventing or reducing adverse effects in a patient | PERICOR THERAPEUTICS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20150272978-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | PERICOR THERAPEUTICS, INC. | 2015-10-01 | — | — | US | disclosed |
| US-20150272978-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | PERICOR THERAPEUTICS, INC. | 2015-10-01 | — | — | US | disclosed |
| US-8993527-B2 | Methods, compositions, and formulations for preventing or reducing adverse effects in a patient | PERICOR THERAPEUTICS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993527-B2 | Methods, compositions, and formulations for preventing or reducing adverse effects in a patient | PERICOR THERAPEUTICS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8569267-B2 | Tetracyclic tetrahydrofuran derivatives containing cyclic amine side chain | JANSSEN PHARMACEUTICA, NV (BE) | 2013-10-29 | — | — | US | disclosed |
| US-20090005545-A1 | METHODS FOR PURIFYING RADIOLABELLED COMPOUNDS | MCMASTER UNIVERSITY | 2009-01-01 | — | — | US | disclosed |
| US-20080262076-A1 | Novel Tetracyclic Tetrahydrofuran Derivatives Containing Cyclic Amine Side Chain | JANSSEN PHARMACEUTICA, NV (BE) | 2008-10-23 | — | — | US | disclosed |
| US-20080262076-A1 | Novel Tetracyclic Tetrahydrofuran Derivatives Containing Cyclic Amine Side Chain | JANSSEN PHARMACEUTICA, NV (BE) | 2008-10-23 | — | — | US | disclosed |
| US-7335347-B2 | Methods for purifying radiolabelled compounds | MCMASTER UNIVERSITY (CA) | 2008-02-26 | — | — | US | disclosed |
| US-5006556-A | Dichloroaniline derivatives for the therapy or prophylaxysis of a disease associated with reversible airway obstruction | GLAXO GROUP LIMITED (GB) | 1991-04-09 | — | — | US | disclosed |
| US-4943591-A | TREATMENT OF ASTHMA AND BRONCHITIS | GLAXO GROUP LIMITED (GB) | 1990-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150272978-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | TNNC1, ASAH2, PGF | NPSR1 863/4885KMT2A 2661/4885HDAC1 937/4885 |
| US-20080262076-A1 | Novel Tetracyclic Tetrahydrofuran Derivatives Containing Cyclic Amine Side Chain | HTR2C, HTR2A, HTR5A | NPSR1 70/4885KMT2A 1892/4885HDAC1 1424/4885 |
| US-20170216335-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | TNNC1, ASAH2, PGF | NPSR1 863/4885KMT2A 2661/4885HDAC1 937/4885 |
| US-20090005545-A1 | METHODS FOR PURIFYING RADIOLABELLED COMPOUNDS | PAICS, PFAS, NPEPPS | NPSR1 684/4885KMT2A 2099/4885HDAC1 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.